Santhera’s Agamree (vamorolone) for the rare disease Duchenne muscular dystrophy (DMD) is among seven new drugs the European Medicines Agency has said should be approved for marketing in the EU.
The EMA’s human medicines committee, the CHMP, recommended that Agamree, which has orphan status, be approved for the treatment of DMD in children and adults aged four years and older
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?